drugset / Trial / NCT06362590

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT06362590

Expanded access Available Seagen Inc.

Summary

The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background ladiratuzumab vedotin Unknown

Indications

No indication recorded.